ES2712052T3 - Métodos para reducir partículas de LDL pequeñas y densas - Google Patents

Métodos para reducir partículas de LDL pequeñas y densas Download PDF

Info

Publication number
ES2712052T3
ES2712052T3 ES09821200T ES09821200T ES2712052T3 ES 2712052 T3 ES2712052 T3 ES 2712052T3 ES 09821200 T ES09821200 T ES 09821200T ES 09821200 T ES09821200 T ES 09821200T ES 2712052 T3 ES2712052 T3 ES 2712052T3
Authority
ES
Spain
Prior art keywords
ldl
compound
pattern
particle size
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09821200T
Other languages
English (en)
Spanish (es)
Inventor
David B Karpf
Ronald M Krauss
Yun-Jung Choi
Xueyan Wang
Francine M Gregoire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Application granted granted Critical
Publication of ES2712052T3 publication Critical patent/ES2712052T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09821200T 2008-10-17 2009-10-14 Métodos para reducir partículas de LDL pequeñas y densas Active ES2712052T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10648308P 2008-10-17 2008-10-17
PCT/US2009/060679 WO2010045361A1 (en) 2008-10-17 2009-10-14 Methods of reducing small, dense ldl particles

Publications (1)

Publication Number Publication Date
ES2712052T3 true ES2712052T3 (es) 2019-05-09

Family

ID=42106878

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09821200T Active ES2712052T3 (es) 2008-10-17 2009-10-14 Métodos para reducir partículas de LDL pequeñas y densas

Country Status (11)

Country Link
US (3) US20100152295A1 (enExample)
EP (1) EP2346498B1 (enExample)
JP (1) JP5694941B2 (enExample)
KR (1) KR20110091680A (enExample)
CN (1) CN102209532B (enExample)
BR (1) BRPI0920170A2 (enExample)
CA (1) CA2740874C (enExample)
ES (1) ES2712052T3 (enExample)
MX (1) MX2011004077A (enExample)
TW (1) TWI491392B (enExample)
WO (1) WO2010045361A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
UA124019C2 (uk) * 2016-10-05 2021-07-07 Мітобрідж, Інк. Спосіб лікування гострого пошкодження нирок
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3068213D1 (en) 1979-09-05 1984-07-19 Glaxo Group Ltd Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
JP4790969B2 (ja) 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
JPWO2002046154A1 (ja) 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004537525A (ja) 2001-06-11 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド ＰＰＡＲδアゴニストの投与による炎症性疾患の治療法
GB0121436D0 (en) * 2001-09-04 2001-10-24 Pfizer Ltd Biomodulated multiparticulate formulations
US20060258683A1 (en) * 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
UA87467C2 (xx) * 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ES2701094T3 (es) * 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) * 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash

Also Published As

Publication number Publication date
BRPI0920170A2 (pt) 2016-06-21
JP2012505905A (ja) 2012-03-08
US20190298672A1 (en) 2019-10-03
CA2740874C (en) 2018-02-27
KR20110091680A (ko) 2011-08-12
US11007162B2 (en) 2021-05-18
MX2011004077A (es) 2011-08-17
TWI491392B (zh) 2015-07-11
CA2740874A1 (en) 2010-04-22
WO2010045361A1 (en) 2010-04-22
US20160324811A1 (en) 2016-11-10
JP5694941B2 (ja) 2015-04-01
CN102209532B (zh) 2015-07-22
CN102209532A (zh) 2011-10-05
US20100152295A1 (en) 2010-06-17
EP2346498A4 (en) 2012-08-01
TW201028141A (en) 2010-08-01
EP2346498A1 (en) 2011-07-27
EP2346498B1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
EP2346498B1 (en) Methods of reducing small, dense ldl particles
ES2535427T3 (es) Sales de lisina nuevas de derivados de 4-((fenoxialquil)tio)-fenoxi ácido acético
TWI388317B (zh) ４-（（苯氧基烷基）硫基）-苯氧基乙酸類及類似物（一）
ES2546202T3 (es) Ácidos y análogos 4-(tio(fenoxialquil)) - fenoxiacético
HK1159492B (en) Methods of reducing small, dense ldl particles
HK1159492A (en) Methods of reducing small, dense ldl particles
HK1122699B (en) Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives